ZyVersa Therapeutics, Inc.
ZVSA
$0.6794
-$0.0306-4.31%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.93M | 7.36M | 7.71M | 8.11M | 9.99M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.45M | 9.14M | 9.63M | 10.26M | 12.66M |
| Operating Income | -8.45M | -9.14M | -9.63M | -10.26M | -12.66M |
| Income Before Tax | -8.84M | -9.41M | -21.92M | -22.42M | -105.99M |
| Income Tax Expenses | 6.70K | 6.70K | -586.40K | -586.90K | -8.41M |
| Earnings from Continuing Operations | -8.84 | -9.41 | -21.33 | -21.83 | -97.58 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.84M | -9.41M | -21.33M | -21.83M | -97.58M |
| EBIT | -8.45M | -9.14M | -9.63M | -10.26M | -12.66M |
| EBITDA | -8.45M | -9.13M | -9.62M | -10.25M | -12.64M |
| EPS Basic | -7.18 | -10.99 | -72.35 | -100.10 | -1.79K |
| Normalized Basic EPS | -4.48 | -6.86 | -11.58 | -28.72 | -89.75 |
| EPS Diluted | -7.18 | -10.99 | -72.35 | -100.10 | -1.79K |
| Normalized Diluted EPS | -4.48 | -6.86 | -11.58 | -28.72 | -89.75 |
| Average Basic Shares Outstanding | 6.92M | 4.44M | 2.66M | 1.77M | 986.80K |
| Average Diluted Shares Outstanding | 6.92M | 4.44M | 2.66M | 1.77M | 986.80K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |